New Vaxzevria data further support its use as third dose booster
New data from ongoing trial showed increased antibody response against Beta, Delta, Alpha and Gamma variants following third dose booster with Vaxzevria.Additional analysis showed increased antibody response to Omicron after a third dose.Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that Vaxzevria (ChAdOx1-S [Recombinant]), when given as a third dose booster, increased the immune response to Beta, Delta, Alpha and Gamma SARS-CoV-2 variants, while a separate analysis of samples from the trial showed increased antibody